Aktis Oncology, Inc.
AKTSNASDAQHealthcare● Active
$18.97
+$0.10(+0.53%)
Market Cap$1.0B
P/E Ratio—
52W High$29.16
52W Low$14.72
Aktis Oncology, Inc.（AKTS）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AKTS · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $6.50M | $1.49M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $6.50M | $1.49M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | — | — |
| Operating Expenses | ||||
| R&D Expenses | $67.45M | $40.95M | $25.92M | $14.30M |
| G&A Expenses | $12.60M | $11.31M | $7.68M | $5.11M |
| Total Operating Expenses | $81.18M | $53.54M | $34.79M | $19.76M |
| Operating Income | ($74.68M) | ($52.05M) | ($34.79M) | ($19.76M) |
| Operating Margin %(computed) | — | — | — | — |
| Interest Income | $11.01M | $8.10M | $5.38M | $1.65M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($63.73M) | ($43.98M) | ($28.64M) | ($17.93M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($63.73M) | ($43.98M) | ($28.64M) | ($17.93M) |
| Net Margin %(computed) | -980.93% | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-1.19 | $-1.26 | $-0.82 | $-0.51 |
| Wtd Avg Shares | 52.52M | 34.86M | 34.86M | 34.86M |
| EBITDA | ($72.36M) | ($50.48M) | ($33.60M) | ($19.32M) |
| EBITDA Margin %(computed) | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Aktis Oncology, Inc.
关于Aktis Oncology, Inc.（AKTS）损益表
Aktis Oncology, Inc.（AKTS）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，AKTS实现营收$0.01B，毛利润$0.01B（毛利率100.00%），净利润($0.06B)（净利率-980.93%）。
常见问题
AKTS · 4 问Aktis Oncology, Inc.（AKTS）2025财年营收为$0.01B，同比up336.9%。
AKTS revenueAKTS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09